Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234076 | 0.84 | HDAC1 (0.69) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL12672064 | 0.80 | MEN1 (0.81) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL2808670 | 0.80 | MEN1 (0.81) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL12672513 | 0.80 | HDAC1 (0.64) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL1231733 | 0.80 | HDAC1 (0.64) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL1305483 | 0.80 | MEN1 (0.67) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL1233057 | 0.79 | MEN1 (0.83) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL4365637 | 0.78 | HDAC8 (0.64) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL7612256 | 0.78 | MEN1 (0.47) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL12672626 | 0.78 | HDAC1 (0.65) | HDAC1HDAC2HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-2083005-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1598067-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC2 8/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.